Pharmacogenomics of hypertension: A realizable goal?

Clinical Science

Volumn 99, Issue 3, 2000, Pages 231-232

  Samani, N J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RECEPTOR SUBTYPE;

ADULT; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COST; COST EFFECTIVENESS ANALYSIS; DNA POLYMORPHISM; ESSENTIAL HYPERTENSION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; PHARMACOGENOMICS; PRIORITY JOURNAL; RACE DIFFERENCE; RECEPTOR GENE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; TREATMENT INDICATION;

EID: 0033821174     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs0990231     Document Type: Short Survey

References (8)

1. Optimisation of antihypertensive treatment by crossover rotation of four major classes
2. Renin profiling for diagnosis, risk assessment, and treatment of hypertension
3. Molecular genetics of human hypertension
4. Adducin polymorphism affects renal proximal tubule reabsorption in hypertension
5. The role of α-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study
6. Association of hypertension with T594M mutation in β subunit of epithelial sodium channels in black people resident in London
7. 1-adrenoceptor does not influence blood pressure or heart rate response to β-blockade in hypertensive subjects
8. 1-adrenergic receptor